Home > Boards > US Listed > Biotechs > Sernova Corp. (SEOVF)

Sernova SVA.V Sketches of Progress - How Disruptive

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
StruckGold Member Profile
 
Followed By 2
Posts 107
Boards Moderated 0
Alias Born 04/20/12
160x600 placeholder
StruckGold   Monday, 04/11/16 08:20:28 AM
Re: None
Post # of 37 

Sernova SVA.V Sketches of Progress - How Disruptive Technologies Reshape our World. Billion Dollar opportunity for 0.25c per share.


March 29, 2016 12:45 PM

PRINCE GEORGE, BC / ACCESSWIRE / March 29, 2016 / Disruptive innovations have the potential to truly reshape the world in which we live and work.

Regenerative medicine means replacing, engineering or regenerating human cells, tissues or organs with the goal being to re-establish normality for conditions that currently are beyond repair.

An example of a highly disruptive technology is regenerative medicine where living therapeutic cells placed within an implanted medical device manufacture and release required medicines into the body as needed.

For diabetes, this technology has the potential to disrupt the entire multibillion insulin and insulin pump market as the therapeutic cells can read blood sugar levels and manufacture and release all the hormones required to appropriately control blood sugar. The same can occur in other therapeutic areas such as hemophilia where Factor VIII can be produced by therapeutic cells within an implanted device rather than being infused multiple times weekly.

Sernova Corp. (TSX.V: SVA; OTCQB: SEOVF) has a technology platform with the potential to do multiple deals based on disease indication, cell type and/or device technology. A potential licensee Company, depending on their needs, might require Sernova's Cell Pouch™ technology, Stem Cell-Derived Therapeutic cells or Sernova's developing technology which protects the therapeutic cells inside their Cell Pouch™ from the body's immune system. They may be focused on a single clinical indication such as diabetes or more than one. Deals could be done regionally or globally depending on the need.

There are many companies operating in the regenerative medicine space whose products have the potential to be disrupted and each is a potential suitor for one, or more, of Sernova's technologies.

For the complete report on Aheadoftheherd.com: http://aheadoftheherd.com/Newsletter/2016/Sketches-Of-Progress.html.

About the author: Richard (Rick) Mills, Editor of www.Aheadoftheherd.com

Richard invests in the resource and biotechnology/pharmaceutical sectors and is the owner of http:www.Aheadoftheherd.com. His articles have been published on over 400 websites, including:

WallStreetJournal, USAToday, NationalPost, Lewrockwell, MontrealGazette, VancouverSun, CBSnews, HuffingtonPost, Beforeitsnews, Londonthenews, Wealthwire, CalgaryHerald, Forbes, Dallasnews, SGTreport, Vantagewire, Indiatimes, Ninemsn, Ibtimes, Businessweek, HongKongHerald, Moneytalks, SeekingAlpha, BusinessInsider, Investing.com, MSN.com and the Association of Mining Analysts. For more information about his newsletter, log on to: http:www.Aheadoftheherd.com.

Media contact:

Jackie Rodriguez
646-430-5783

SOURCE: Aheadoftheherd.com



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences